Literature DB >> 11964599

Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein.

Christoph Wandel1, Richard Kim, Margaret Wood, Alastair Wood.   

Abstract

BACKGROUND: The efflux transporter P-glycoprotein, a member of the adenosine triphosphate-binding cassette superfamily, is a major determinant of the pharmacokinetics and pharmacodynamics of the opioid loperamide, a well-recognized antidiarrheal agent. Animal studies indicate that P-glycoprotein limits morphine entry into the brain. In this study, the authors examined whether other opioids of importance to anesthesiologists such as fentanyl, sufentanil, and alfentanil, and also morphine-6-glucuronide and morphine-3-glucuronide, are P-glycoprotein substrates and whether, in turn, these opioids act also as P-glycoprotein inhibitors.
METHODS: The transcellular movement of the various opioids, including loperamide and morphine, was assessed in L-MDR1 (expressing P-glycoprotein) and LLC-PK1 cell monolayers (P-glycoprotein expression absent). A preferential basal-to-apical versus apical-to-basal transport in the L-MDR cells but not the LLC-PK1 cells is seen for P-glycoprotein substrates. In addition, the effect of the various opioids on the transcellular movement of the prototypical P-glycoprotein substrate digoxin was examined in Caco-2 cell monolayers. IC50 values were calculated according to the Hill equation.
RESULTS: Loperamide was a substrate showing high dependence on P-glycoprotein in that basal-apical transport was nearly 10-fold greater than in the apical-basal direction in L-MDRI cells. Morphine also showed a basal-to-apical gradient in the L-MDR1 cell monolayer, indicating that it too is a P-glycoprotein substrate, but with less dependence than loperamide in that only 1.5-fold greater basal-apical directional transport was observed. Fentanyl, sufentanil, and alfentanil did not behave as P-glycoprotein substrates, whereas the morphine glucuronides did not cross the cell monolayers at all, whether P-glycoprotein was present or not. Loperamide, sufentanil, fentanyl, and alfentanil inhibited P-glycoprotein-mediated digoxin transport in Caco-2 cells with IC50 values of 2.5, 4.5, 6.5, and 112 microm, respectively. Morphine and its glucuronides (20 microm) did not inhibit digoxin (5 microm) transport in Caco-2 cells, and therefore IC50 values were not determined.
CONCLUSIONS: Opioids have a wide spectrum of P-glycoprotein activity, acting as both substrates and inhibitors, which might contribute to their varying central nervous system-related effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11964599     DOI: 10.1097/00000542-200204000-00019

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  63 in total

1.  Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene.

Authors:  Nicole Soranzo; Gianpiero L Cavalleri; Michael E Weale; Nicholas W Wood; Chantal Depondt; Richard Marguerie; Sanjay M Sisodiya; David B Goldstein
Journal:  Genome Res       Date:  2004-06-14       Impact factor: 9.043

2.  Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes.

Authors:  Kyoung-Ah Kim; Jaegul Chung; Dong-Hae Jung; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2004-09-08       Impact factor: 2.953

Review 3.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

4.  Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.

Authors:  Juha Grönlund; Teijo I Saari; Nora M Hagelberg; Pertti J Neuvonen; Klaus T Olkkola; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

5.  Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition.

Authors:  J Cory Kalvass; Gary M Pollack
Journal:  Pharm Res       Date:  2006-12-27       Impact factor: 4.200

6.  Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?

Authors:  Sven Björkman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 7.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

8.  Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.

Authors:  Hazem E Hassan; Alan L Myers; Andrew Coop; Natalie D Eddington
Journal:  J Pharm Sci       Date:  2009-12       Impact factor: 3.534

9.  Morphine and the blood-brain barrier: diffusion, uptake, or efflux?

Authors:  Karsten Bartels; Konrad Meissner
Journal:  Can J Anaesth       Date:  2017-07-18       Impact factor: 5.063

10.  Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux.

Authors:  D Groenendaal; J Freijer; D de Mik; M R Bouw; M Danhof; E C M de Lange
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.